Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Por um escritor misterioso
Descrição

Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. - Abstract - Europe PMC

PDF) Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Frontiers Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

Frontiers Therapeutic strategies for gastric cancer targeting immune cells: Future directions

PDF) Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Full article: Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

Wnt/β-catenin signaling in cancers and targeted therapies

Vaccines, Free Full-Text

Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
de
por adulto (o preço varia de acordo com o tamanho do grupo)